Our first target population is ventilated pneumonia patients, who currently receive antibiotics intravenously, resulting in limited drug concentrations in the lungs, leading to a 33 day average hospitalization and 15% mortality.

Mucus obstructions in the airways can hinder the passage of aerosols into infected lung regions, and thereby dramatically reducing the effectiveness of such treatment, which have failed in clinical trials.

Our LiFT RapidHeal™ technology can deliver 100-fold higher concentrations directly into the lungs compared to standard-of-care, such concentrations are known from the literature to kill resistant bacteria. Additionally, the foam’s unique fluid properties hold the potential to reach the infection beyond mucus obstructions and airway narrowings in sufficient concentrations to eliminate the bacterial infection.

In the future, Neshima will leverage LiFT™ technology to address numerous additional unmet clinical needs. These include treatments for various types of pneumonia (other bacteria, viral, and fungal), airway washes to remove mucus, and fast-acting bronchodilator rescue therapy for severe asthma. Neshima’s moonshot vision is to deliver stem cells directly into emphysematous regions to regenerate the lungs of COPD patients.